|Title:||Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia|
|Abstract:||Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.|
|Inventor(s):|| Cartt; Steve (Union City, CA) |
|Assignee:|| Questcor Pharmaceuticals, Inc. (Union City, CA) |
1. A method for reducing the risk of an adverse drug interaction in a patient suffering from depression, comprising (i) determining if the patient is also suffering from
insomnia and is being treated with bupropion, and (ii) prescribing or administering to the patient a therapeutically effective amount of quazepam to treat the insomnia if and only if the patient is not being treated with bupropion.
2. The method of claim 1, wherein the patient is not being treated with bupropion, further comprising prescribing or administering to the patient an antidepressant drug other than bupropion.